Sickle Cell Disease
Anemia Management
Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (opens new window)
Source: Eur J Haematol 1996;56(5):326-8.
Indexed: PubMed 8641410
https://www.ncbi.nlm.nih.gov/pubmed/8641410 (opens new window)
On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (opens new window)
Source: Acta Haematol 1995;94(3):128-34.
Indexed: PubMed 7502628
https://www.ncbi.nlm.nih.gov/pubmed/7502628 (opens new window)
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (opens new window)
Source: Haematologica 2006;91(8):1076-83.
Indexed: PubMed 16885048
https://www.ncbi.nlm.nih.gov/pubmed/16885048 (opens new window)
Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (opens new window)
Source: J Obstet Gynaecol 2007;27(1):82-3.
Indexed: PubMed 17365469
DOI: 10.1080/01443610601062739
https://www.ncbi.nlm.nih.gov/pubmed/17365469 (opens new window)
The use of barbiturate coma as salvage therapy in a postoperative Jehovah's Witness patient with life-threatening anemia. (opens new window)
Source: Am Surg 2009;75(12):1175-8.
Indexed: PubMed 19999907
https://www.ncbi.nlm.nih.gov/pubmed/19999907 (opens new window)